The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.

@article{Cheong2015TheEO,
  title={The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.},
  author={Su-Jin Cheong and C Lee and Eun-Mi Kim and Seok Tae Lim and Myung-Hee Sohn and Hwan-Jeong Jeong},
  journal={Nuclear medicine and biology},
  year={2015},
  volume={42 2},
  pages={85-91}
}
INTRODUCTION (18)F-2-deoxy-2-fluoro-d-glucose ((18)F-FDG) positron emission tomography (PET) has been used for imaging human cancers for several decades. Despite its extensive use, (18)F-FDG PET imaging has limitations in the tumor findings. The goal of this study was to investigate the potential of a PPAR-γ agonist pioglitazone (PIO) to distinguish tumors and inflammatory lesions in (18)F-FDG PET imaging. METHODS Studies of cellular uptake of (18)F-FDG and Western blot were performed in… CONTINUE READING